Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Cited In for PubMed (Select 22010915)

1.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.

2.

Mycobacterium tuberculosis: 2014 Clinical trials in review.

Laupland KB, Valiquette L.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):11-4. No abstract available.

3.

A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa.

van Loggerenberg F, Gray D, Gengiah S, Kunene P, Gengiah TN, Naidoo K, Grant AD.

AIDS Patient Care STDS. 2015 May;29(5):299-306. doi: 10.1089/apc.2014.0293. Epub 2015 Feb 18.

4.

Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study.

Crump JA, Wu X, Kendall MA, Ive PD, Kumwenda JJ, Grinsztejn B, Jentsch U, Swindells S.

BMC Infect Dis. 2015 Jan 13;15(1):12. doi: 10.1186/s12879-014-0735-5.

5.

Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review.

Wajanga BM, Webster LE, Peck RN, Downs JA, Mate K, Smart LR, Fitzgerald DW.

BMC Health Serv Res. 2014 Dec 3;14(1):627. doi: 10.1186/s12913-014-0627-9.

6.

The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.

Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM.

PLoS One. 2014 Nov 12;9(11):e112017. doi: 10.1371/journal.pone.0112017. eCollection 2014.

7.

Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome.

Andrade BB, Singh A, Narendran G, Schechter ME, Nayak K, Subramanian S, Anbalagan S, Jensen SM, Porter BO, Antonelli LR, Wilkinson KA, Wilkinson RJ, Meintjes G, van der Plas H, Follmann D, Barber DL, Swaminathan S, Sher A, Sereti I.

PLoS Pathog. 2014 Oct 2;10(10):e1004433. doi: 10.1371/journal.ppat.1004433. eCollection 2014 Oct.

8.

Update on opportunistic infections in the era of effective antiretroviral therapy.

Zanoni BC, Gandhi RT.

Infect Dis Clin North Am. 2014 Sep;28(3):501-18. doi: 10.1016/j.idc.2014.05.002. Review.

PMID:
25151568
9.

Antiretroviral therapy: when to start.

Sellers CJ, Wohl DA.

Infect Dis Clin North Am. 2014 Sep;28(3):403-20. doi: 10.1016/j.idc.2014.05.004. Review.

PMID:
25151563
10.

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline.

Leibert E, Danckers M, Rom WN.

Ther Clin Risk Manag. 2014 Jul 29;10:597-602. doi: 10.2147/TCRM.S37743. eCollection 2014. Review.

11.

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; TSHEPISO Study Team.

J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31.

PMID:
25081933
12.

Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G; COAT Trial Team.

N Engl J Med. 2014 Jun 26;370(26):2487-98. doi: 10.1056/NEJMoa1312884.

13.

Tuberculosis in tropical areas and immigrants.

Zammarchi L, Bartalesi F, Bartoloni A.

Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014043. doi: 10.4084/MJHID.2014.043. eCollection 2014. Review.

14.

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group A5306 Study Team.

Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52. doi: 10.1128/AAC.03332-14. Epub 2014 Jun 23.

15.

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.

Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group.

J Int AIDS Soc. 2014 Jun 17;17:19034. doi: 10.7448/IAS.17.1.19034. eCollection 2014.

16.

The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study.

Yang CH, Chen KJ, Tsai JJ, Lin YH, Cheng SH, Wang KF, Chiou HY.

BMC Infect Dis. 2014 Jun 4;14:304. doi: 10.1186/1471-2334-14-304.

17.

Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011).

Kaplan R, Caldwell J, Middelkoop K, Bekker LG, Wood R.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):487-94. doi: 10.1097/QAI.0000000000000201.

PMID:
24820105
18.

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team.

Clin Infect Dis. 2014 Aug 1;59(3):435-45. doi: 10.1093/cid/ciu283. Epub 2014 Apr 23.

PMID:
24759827
19.

Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trial.

van Loggerenberg F, Grant AD, Naidoo K, Murrman M, Gengiah S, Gengiah TN, Fielding K, Abdool Karim SS.

AIDS Behav. 2015 Jan;19(1):145-56. doi: 10.1007/s10461-014-0763-6.

PMID:
24696226
20.

Recent advances in tuberculosis: New drugs and treatment regimens.

Sloan DJ, Davies GR, Khoo SH.

Curr Respir Med Rev. 2013 Jun 1;9(3):200-210.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk